Price
No data yet.
Social Signal Score
Revenue
$145.85M+222.88%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Christian Wojczewski
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 4,553
- Beta
- 1.26
- Country
- DE
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -0.07
Financials
Revenue
$145.85M+222.9%Net Income
$-47.42M-637.5%EBITDA
$-27.13M-327.4%Free Cash Flow
$-119.54M-1756.0%EPS (diluted)
$-0.13-471.4%Shares Outstanding (diluted)
355.53M+34.1%Operating Expenses
$50.37MCash & Debt
$465.59MReturn of Capital
$0.00Revenue by Segment (annual)
$300.0KDividend per Share
$0.07Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $757.26M | $-99.43M | $-0.28 |
| 2024 | $796.97M | $-196.08M | $-0.56 |
| 2023 | $781.43M | $-83.91M | $-0.23 |
| 2022 | $751.45M | $-175.66M | $-0.49 |
| 2021 | $618.03M | $215.51M | $0.65 |
| 2020 | $500.92M | $6.28M | $0.02 |
| 2019 | $446.44M | $38.16M | $0.13 |
| 2018 | $375.40M | $84.17M | $0.28 |
| 2017 | $257.63M | $24.26M | $0.08 |
| 2016 | $164.51M | $27.53M | $0.10 |
| 2015 | $127.68M | $16.52M | $0.07 |
| 2014 | $89.50M | $-6.98M | $-0.03 |
| 2013 | $85.94M | $-25.43M | $-0.10 |
| 2012 | $87.27M | $2.48M | $0.01 |
Valuation
EVOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100-16.67%Social Signal Score
Mentions (2)
- Newsbusinesswire.com·5h ago·Neutral
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced top-line results from its randomized, double-blind, placebo controlled dose-ranging Phase 2b trial evaluating the efficacy and safety of oral Mas-…
View source ↗ - Newsprnewswire.com·6d ago·Positive
… precision of T cell activation based on multispecific antigen signature HAMBURG, Germany and HALLBERGMOOS, Germany, Sept. 2, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) and Plectonic Biotech today announced a research collaboration to explore a novel immunotherapy approach for solid tumors.
View source ↗
Earnings
Thu, Nov 5(in 8 weeks)
Consensus estimate $-0.31 per share
Typical surprise -74.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.17 vs $-0.05miss
- Wed, May 6$-0.46 vs $-0.15miss
- Wed, Apr 8$0.05 vs $0.21miss
- Wed, Nov 5$-0.14 vs $-0.14miss
- Wed, Aug 13$-0.14 vs $-0.18beat
- Tue, May 6$-0.15 vs $-0.11miss
Estimates and results for EVO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by EVO officers and directors.
- Bought
- $5k
- Sold
- $5k
3 trades
3 trades
- Bank Of America Corp /de/bought
- Bank Of America Corp /de/sold
- Bank Of America Corp /de/bought
- Bank Of America Corp /de/sold
- Bank Of America Corp /de/bought
- Bank Of America Corp /de/sold
40 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.